| pubmed-article:9156803 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9156803 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9156803 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
| pubmed-article:9156803 | lifeskim:mentions | umls-concept:C0027627 | lld:lifeskim |
| pubmed-article:9156803 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:9156803 | lifeskim:mentions | umls-concept:C0879590 | lld:lifeskim |
| pubmed-article:9156803 | lifeskim:mentions | umls-concept:C0443211 | lld:lifeskim |
| pubmed-article:9156803 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:9156803 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:9156803 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9156803 | pubmed:dateCreated | 1997-5-20 | lld:pubmed |
| pubmed-article:9156803 | pubmed:abstractText | IL-2 and IL-6 are important cytokines which have potent antitumor effects and can cooperate to induce immune responses more effectively. IL-2 gene or IL-6 gene-transfected tumor cells exhibited reduced tumorigenicity and decreased metastatic potential. In order to increase the therapeutic efficacy of IL-2 gene-, IL-6 gene-modified tumor vaccines, the experimental pulmonary metastatic melanoma-bearing mice were treated with inactivated IL-2 gene-transfected tumor cells and inactivated IL-6 gene-transfected tumor cells. After the combined vaccination, the pulmonary metastases were reduced more significantly and the survival time of tumor-bearing mice was also markedly prolonged. The CTL activity, NK activity and IL-2-induced LAK activity, IL-2 and TNF secretion from the splenocytes of the above tumor-bearing mice increased more significantly than that of tumor-bearing mice vaccinated with IL-2 gene-transfected vaccine or IL-6 gene transfected vaccine alone. These results demonstrated that the combined use of IL-2 gene-transfected tumor vaccine and IL-6 gene-transfected tumor vaccine could achieve more potent antitumor effect via more effective activation of specific and non-specific antitumor immune responses. | lld:pubmed |
| pubmed-article:9156803 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9156803 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9156803 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9156803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9156803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9156803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9156803 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9156803 | pubmed:month | May | lld:pubmed |
| pubmed-article:9156803 | pubmed:issn | 0969-7128 | lld:pubmed |
| pubmed-article:9156803 | pubmed:author | pubmed-author:ChenCC | lld:pubmed |
| pubmed-article:9156803 | pubmed:author | pubmed-author:TanRR | lld:pubmed |
| pubmed-article:9156803 | pubmed:author | pubmed-author:YuDD | lld:pubmed |
| pubmed-article:9156803 | pubmed:author | pubmed-author:YoSS | lld:pubmed |
| pubmed-article:9156803 | pubmed:author | pubmed-author:ZhangWW | lld:pubmed |
| pubmed-article:9156803 | pubmed:author | pubmed-author:CaoXX | lld:pubmed |
| pubmed-article:9156803 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9156803 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:9156803 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9156803 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9156803 | pubmed:pagination | 421-6 | lld:pubmed |
| pubmed-article:9156803 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:meshHeading | pubmed-meshheading:9156803-... | lld:pubmed |
| pubmed-article:9156803 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:9156803 | pubmed:articleTitle | Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. | lld:pubmed |
| pubmed-article:9156803 | pubmed:affiliation | Department of Immunology, Second Military Medical University, Shanghai, PR China. | lld:pubmed |
| pubmed-article:9156803 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9156803 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9156803 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9156803 | lld:pubmed |
